The Clinical Trials Office (CTO) provides administrative, research and educational services to the CancerInstitute investigators and research staff conducting clinical trials. It serves as the main coordinating centerfor cancer-related clinical trials from concept development and submission to closure including protocoldevelopment, regulatory and compliance guidance, administrative submissions, data collection and datamanagement, data analysis, and quality control functions, and serves as the administrative interface to otherclinical research organizations at the NYU Medical Center. The goals of this resource are to:Facilitate clinical trials by providing a framework for development, submission, and conduct of dinicaltrials.Enhance and facilitate data collection and reporting of clinical cancer research data.Provide educational programs for the CTO staff and clinical investigators.Promote interdisciplinary collaboration and a venue for translating research findings to the clinical arenaIn response to the previous critique, internal audits, and the review of external consultants, significantchanges have occurred within the CTO since the last review. These changes include the appointment ofnew medical and administrative directors, new standard operating procedures, and restructuring of datamanagement. These improvements have produced a CTO that better meets the needs of investigatorsperforms more effectively within the NYU School of Medicine clinical research environment. Currently, theCTO supervises 49 research staff and manages 158 open protocols. The CTO continues to expand andimprove its function to serve as the central coordinating center for the clinical research enterprise at theNYUCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-28
Application #
7714242
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-04-18
Project End
2013-02-28
Budget Start
2008-04-18
Budget End
2009-02-28
Support Year
28
Fiscal Year
2008
Total Cost
$102,845
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Xu, Yang; Taylor, Paul; Andrade, Joshua et al. (2018) Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res 78:6539-6548
Gagner, Jean-Pierre; Zagzag, David (2018) Probing Glioblastoma Tissue Heterogeneity with Laser Capture Microdissection. Methods Mol Biol 1741:209-220
Tsay, Jun-Chieh J; Wu, Benjamin G; Badri, Michelle H et al. (2018) Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 198:1188-1198
Martin, Patricia K; Marchiando, Amanda; Xu, Ruliang et al. (2018) Autophagy proteins suppress protective type I interferon signalling in response to the murine gut microbiota. Nat Microbiol 3:1131-1141
de la Parra, Columba; Ernlund, Amanda; Alard, Amandine et al. (2018) A widespread alternate form of cap-dependent mRNA translation initiation. Nat Commun 9:3068
Coux, Rémi-Xavier; Teixeira, Felipe Karam; Lehmann, Ruth (2018) L(3)mbt and the LINT complex safeguard cellular identity in the Drosophila ovary. Development 145:
Patibandla, Jay R; Fehniger, Julia E; Levine, Douglas A et al. (2018) Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol 149:420-427
Fanok, Melania H; Sun, Amy; Fogli, Laura K et al. (2018) Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. J Invest Dermatol 138:1116-1125
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9
Harper, Lamia; Balasubramanian, Divya; Ohneck, Elizabeth A et al. (2018) Staphylococcus aureus Responds to the Central Metabolite Pyruvate To Regulate Virulence. MBio 9:

Showing the most recent 10 out of 1170 publications